Publication:
Staphylococcus aureus costochondritis and chest wall abscess in a COVID-19 patient treated with tocilizumab

Simple item page
dc.contributor.authorŞANAL TOPRAK, CANAN
dc.contributor.authorODABAŞI, ZEKAVER
dc.contributor.authorsErgenc, Ilkay; Toprak, Canan Sanal; Odabasi, Zekaver
dc.date.accessioned2022-03-12T22:55:15Z
dc.date.accessioned2026-01-11T15:13:44Z
dc.date.available2022-03-12T22:55:15Z
dc.date.issued2021
dc.description.abstractCoronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.
dc.identifier.doi10.5606/tftrd.2021.8208
dc.identifier.eissn2587-1250
dc.identifier.pubmed34870129
dc.identifier.urihttps://hdl.handle.net/11424/236693
dc.identifier.wosWOS:000692197000018
dc.language.isoeng
dc.publisherBAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK
dc.relation.ispartofTURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAbscess
dc.subjectchest wall
dc.subjectcostochondritis
dc.subjectCOVID-19
dc.subjecttocilizumab
dc.subjectSERIOUS INFECTIONS
dc.subjectRISK
dc.titleStaphylococcus aureus costochondritis and chest wall abscess in a COVID-19 patient treated with tocilizumab
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage385
oaire.citation.issue3
oaire.citation.startPage382
oaire.citation.titleTURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION
oaire.citation.volume67

Files

Collections

Araştırma Çıktıları